BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s share price was down 1.8% during trading on Monday . The stock traded as low as $39.88 and last traded at $40.92, with a volume of 57,176 shares trading hands. The stock had previously closed at $41.69.

A number of brokerages have issued reports on BSTC. Rodman & Renshaw reiterated a “buy” rating on shares of BioSpecifics Technologies Corp. in a research note on Monday, June 13th. Zacks Investment Research upgraded shares of BioSpecifics Technologies Corp. from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, May 10th.

The stock has a 50 day moving average price of $38.40 and a 200 day moving average price of $37.05. The stock has a market cap of $288.06 million and a PE ratio of 29.53.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.02. The business had revenue of $6.60 million for the quarter, compared to the consensus estimate of $6.25 million. Analysts predict that BioSpecifics Technologies Corp. will post $1.40 EPS for the current fiscal year.

In related news, major shareholder Thomas Wegman sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $33.01, for a total transaction of $1,650,500.00. Following the completion of the transaction, the insider now owns 220,772 shares in the company, valued at $7,287,683.72. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Toby Wegman sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $33.01, for a total value of $825,250.00. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in shares of BioSpecifics Technologies Corp. by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 168,874 shares of the biopharmaceutical company’s stock worth $7,257,000 after buying an additional 11,456 shares in the last quarter. Mutual of America Capital Management LLC increased its position in shares of BioSpecifics Technologies Corp. by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 56,647 shares of the biopharmaceutical company’s stock worth $2,434,000 after buying an additional 337 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of BioSpecifics Technologies Corp. by 34.6% in the fourth quarter. GSA Capital Partners LLP now owns 91,347 shares of the biopharmaceutical company’s stock worth $3,925,000 after buying an additional 23,500 shares in the last quarter. EAM Investors LLC increased its position in shares of BioSpecifics Technologies Corp. by 34.6% in the fourth quarter. EAM Investors LLC now owns 111,866 shares of the biopharmaceutical company’s stock worth $4,807,000 after buying an additional 28,752 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of BioSpecifics Technologies Corp. by 17.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 73,803 shares of the biopharmaceutical company’s stock worth $3,171,000 after buying an additional 11,230 shares in the last quarter.

BioSpecifics Technologies Corp. is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.